IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. (April 2022)

Record Type:
Journal Article
Title:
IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. (April 2022)
Main Title:
IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis
Authors:
Huang, C.N.
Tsou, S.H.
Li, H.H.
Lin, S.C.
Lin, C.L.
Abstract:
Is Part Of:
Diabetes research and clinical practice. Volume 186:Supplement 1(2022)
Journal:
Diabetes research and clinical practice
Issue:
Volume 186:Supplement 1(2022)
Issue Display:
Volume 186, Issue 1 (2022)
Year:
2022
Volume:
186
Issue:
1
Issue Sort Value:
2022-0186-0001-0000
Page Start:
Page End:
Publication Date:
2022-04
Subjects:
Diabetes -- Periodicals
Diabetes Mellitus -- Periodicals
616.462
Journal URLs:
http://www.sciencedirect.com/science/journal/01688227 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01688227 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01688227 ↗
http://www.sciencedirect.com/science/journal/01688227 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/j.diabres.2022.109608 ↗
Languages:
English
ISSNs:
0168-8227
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 3579.603700
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
21917.xml